Investigation of linerixibat 40 mg BID for cholestatic pruritus of ...

S19 Investigation of Linerixibat 40 Mg BID for Cholestatic...

S19 Investigation of Linerixibat 40 Mg BID for Cholestatic Pruritus of Primary Biliary Cholangitis; Further Data From the Phase 2b GLIMMER Study to Support the ...

Investigation of linerixibat 40 mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from the Phase 2b GLIMMER ...

S19 Investigation of Linerixibat 40 Mg BID for Cholestatic Pruritus of ...

S19 Investigation of Linerixibat 40 Mg BID for Cholestatic Pruritus of Primary Biliary Cholangitis; Further Data From the Phase 2b GLIMMER Study to Support ...

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

0424), 40 mg twice daily (P = .0105), and 90 mg twice ... A well-tolerated dose was identified for Phase 3 investigation for cholestatic pruritus in PBC.

Investigation of linerixibat 40mg BID for cholestatic pruritus of ...

Semantic Scholar extracted view of "Investigation of linerixibat 40mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from ...

GSK presents Phase 2b data on linerixibat for the treatment of ...

... mg once daily or 40, 90mg twice daily linerixibat. Patients in the ... study 201000) conducted in patients with cholestatic pruritus associated ...

A global Phase IIb study of linerixibat for the treatment of cholestatic ...

... study of linerixibat for the treatment of cholestatic pruritus ... The highest proportion of responders was generally in the 40 mg BID group in both populations ...

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

... investigation for cholestatic pruritus in PBC. ClinicalTrials.gov ID ... The linerixibat 40 mg BID group showed significant improvements in the PBC-40 itch ...

linerixibat (GSK2330672) News - LARVOL Sigma

Investigation of Linerixibat 40 mg BID (Twice Daily) for Cholestatic Pruritus of Primary Biliary Cholangitis (PBC) in the Glimmer Phase 2b Study; Further ...

Linerixibat to treat moderate to severe cholestatic pruritus ...

Linerixibat is an oral drug being investigated as a ... In a phase 3 clinical trial, patients take linerixibat by mouth twice daily at a dose of 40 mg. ...

Linerixibat may relieve itch in primary biliary cholangitis-associated ...

After 4 weeks of single-blind placebo, patients received linerixibat once (20 mg, n = 16; 90 mg, n = 23; 180 mg, n = 27) or twice daily (40 mg, ...

A global Phase IIb study of linerixibat for the treatment of cholestatic ...

The highest proportion of responders was generally in the 40 mg BID group in both populations regardless of the responder definition applied.

Linerixibat - an overview | ScienceDirect Topics

The study will include 230 participants with PBC and cholestatic ... 40 mg twice daily application of linerixibat in patients with moderate to severe pruritus.

Health Technology Briefing February 2023

between placebo and linerixibat 180 mg once daily (P = .0424), 40 mg twice ... Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in.

EU Clinical Trials Register

Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus ... 40 mg linerixibat twice daily is planned and ...

Linerixibat dose-response analysis of C4 concentrations as a ...

Linerixibat 40 mg BID. Linerixibat 90 mg BID. Placebo. R. Patients were ... NCT04950127) for the treatment of cholestatic pruritus in primary ...

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

A well-tolerated dose was identified for Phase 3 investigation for cholestatic pruritus in PBC. ... mg QD group and creating a linerixibat 40 mg ...

Relationship between pruritus and sleep in participants with primary ...

... cholestatic pruritus were included in the study. Patients with ... linerixibat (40 mg BID) on sleep interference due to pruritus. This ...

Evaluation and Management of Pruritus in Primary Biliary Cholangitis

... 40 mg twice daily application of linerixibat in patients with moderate to severe pruritus. In 2021, the follow-up Global Linerixibat Itch Study of Efficacy ...

GSK reports positive data from cholestatic pruritus drug trial

It assessed dose response and tolerability of linerixibat at doses of 20mg, 90mg, or 180mg once daily, or 40mg or 90mg twice daily, or placebo, ...